| [1] |
Johri AK, Paoletti LC, Glaser P, et al. Group B Streptococcus: global incidence and vaccine development[J]. Nat Rev Microbiol, 2006, 4(12): 932-942.
|
| [2] |
Heath PT, Feldman RG. Vaccination against group B Streptococcus[J]. Expert Rev Vaccines, 2005, 4(2): 207-218.
|
| [3] |
Edmond KM, Kortsalioudaki C, Scott S, et al. Group B Streptococcal disease in infants aged younger than 3 months: systematic review and Meta-analysis[J]. Lancet, 2012, 379(9815): 547-556.
|
| [4] |
朱敏，范建霞，程利南．围产期B族链球菌感染的研究进展[J]．中华妇产科杂志，2005，40(2)：137-141.
|
| [5] |
Liu H, Zeng H, Wang W, et al. Estimating the burden of invasive Group B Streptococcal disease in young infants in southern mainland China: an observational study[J]. Int J Clin Exp Med, 2015, 8(8): 13699-13707.
|
| [6] |
Wang P, Ma Z, Tong J, et al. Serotype distribution, antimicrobial resistance, and molecular characterization of invasive group B Streptococcus isolates recovered from Chinese neonates[J]. Int J Infect Dis, 2015, 37(2): 115-118.
|
| [7] |
Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B Streptococcal disease: experience in the United States and implications for a potential group B Streptococcal vaccine[J]. Vaccine, 2013, 31(Suppl 4): D20-D26.
|
| [8] |
Johri AK, Lata H, Yadav P, et al. Epidemiology of group B Streptococcus in developing countries[J]. Vaccine, 2013, 31(Suppl 4): D43-D45.
|
| [9] |
Montagu D, Yamey G, Visconti A, et al. Where do poor women in developing countries give birth? A multi-country analysis of demographic and health survey data[J]. PLoS One, 2011, 6(2): e17155.
|
| [10] |
Edwards MS, Gonik B. Preventing the broad spectrum of perinatal morbidity and mortality through group B Streptococcal vaccination[J]. Vaccine, 2013, 31(Suppl 4): D66-D71.
|
| [11] |
Melin P. Neonatal group B Streptococcal disease: from pathogenesis to preventive strategies[J]. Clin Microbiol Infect, 2011, 17(9): 1294-1303.
|
| [12] |
Sweet LR, Gibbs RS.女性生殖道感染性疾病.董建春，王波，译.4版.济南：山东科学技术出版社，2012: 31-45.
|
| [13] |
漆洪波．《孕前和孕期保健指南(第1版)》解读[C]//中华围产医学杂志社．第三届围产医学新进展高峰论坛论文集，重庆，2011.
|
| [14] |
Verani JR, Schrag SJ. Group B Streptococcal disease in infants: progress in prevention and continued challenges[J]. Clin Perinatol，2010, 37(2): 375-392.
|
| [15] |
Verani JR, McGee L, Schrag SJ, et al. Prevention of perinatal group B Streptococcal disease-revised guidelines from CDC, 2010[J]. MMWR Recomm Rep, 2010, 59(RR-10): 1-36.
|
| [16] |
Edwards MS, Fuselier PA, Rench MA, et al. Class specificity of natural1y acquired and vaccine-induced antibody to type Ⅲ group B Streptococcal capsular polysaccharide: determination with a radioimmunoprecipitin assay[J]. Infect Immun, 1984, 44(2): 257-261.
|
| [17] |
Hunter SK, Andracki ME, Krieg AM. Biodegradable microspheres containing group B Streptococcal vaccine: immune response in mice[J]. Am J Obstet Gynecol, 2001, 185(5): 1174-1179.
|
| [18] |
Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B Streptococcal type Ⅲ capsular polysaccharide-tetanus toxoid conjugate vaccine[J]. Vaccine, 2003, 21(24): 3468-3472.
|
| [19] |
Madhi SA, Cutland CL, Jose L, et al. Maternal group B Streptococcus vaccination results in placental antibody transfer without interfering with response to routine infant vaccination[J]. Vaccine, 2014, 31(16): 256-261.
|
| [20] |
Madhi SA, Dangor Z, Heath PT, et al. Considerations for a phase-Ⅲ trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of earlyand late-onset invasive disease in young-infants[J]. Vaccine, 2013, 31(Suppl 4): D52-D57.
|
| [21] |
Mahdi SA, Cutland CL, Jose L，et al. Safety and immunogenicity of an investigational maternal trivalent group B Streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial[J]. Lancet Infect Dis，2016, 16(8): 923-934.
|
| [22] |
Gray BM, Pritchard DG, Dillon HC. Seroepidemiological studies of group B Streptococcus type Ⅱ[J]. J Infect Dis, 1985, 151(6): 1073-1080.
|
| [23] |
Gray BM, Egan ML, Pritchard DG. The group B streptococci: from natural history to the specificity of antibodies[J]. Semin Perinatol, 1990, 14(Suppl 1): 10-21.
|
| [24] |
Lin FY, Philips JB, Azimi PH, et al. Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ⅰa:a multicenter seroepidemiology study[J]. J Infect Dis, 2001, 184(8): 1022-1028.
|
| [25] |
Lin FY, Weisman LE, Azimi PH, et al. Level of maternal IgG anti-group B Streptococcus type Ⅲ antibody correlated with protection of neonates against early-onset disease caused by this pathogen[J]. J Infect Dis, 2004, 190(5): 928-934.
|
| [26] |
Baker CJ, Carey VJ, Rench MA, et al. Maternal antibody at delivery protects neonates from early-onset group B Streptococcal disease[J]. J Infect Dis, 2014, 209(5): 781-788.
|
| [27] |
Gravekamp C, Kasper DL, Paoletti LC, et al. Alpha C protein as a carrier for type Ⅲ capsular polysaccharide and as a protective protein in group B Streptococcal vaccines[J]. Infect Immun, 1999, 67(5): 2491-2496.
|
| [28] |
Bohnsack JF, Widjaja K, Ghazizadeh S, et al. A role for C5 and C5a-ase in the acute neutrophil response to group B Streptococcal infections[J]. J Infect Dis, 1997, 175(8): 847-855.
|
| [29] |
Cheng Q, Carlson B, Pillai S, et al. Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B Streptococci[J]. Infect Immun, 2001, 69(4): 2302-2308.
|
| [30] |
Cheng Q, Debol S, Lam H, et al. Immunization with C5a peptidase or peptidase-type Ⅲ polysaccharide conjugate vaccines enhances learance of group B Streptococci from lungs of infected mice[J]. Infect Immun, 2002, 70(11): 6409-6415.
|
| [31] |
Larsson C, Stalhammar-Carlemalm M, Lindahl G. Experimental vaccination against group B Streptococcus, and encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha[J]. Infect Immun, 1996, 64(6): 3518-3523.
|
| [32] |
Shen X, Lagergård T, Yang Y, et al. Systemic and mucosal immune responses in mice after mucosal immunization with group B Streptococcus type Ⅲ capsular polysaccharide-cholera toxin B subunit conjugate vaccine[J]. Infect Immun, 2000, 68(10): 5749-5755.
|
| [33] |
Maione D, Margarit I, Rinaudo CD, et al. Identification of a universal group B Streptococcus vaccine by multiple genome screen[J]. Science, 2005, 309(15): 148-150.
|
| [34] |
Romero-Saavedra F, Laverde D, Wobser D, et al. Identification of peptidoglycan-associated proteins as vaccine candidates for enterococcal infections[J]. PLoS One, 2014, 9(11): e111880.
|
| [35] |
Fontana MR, Soriani M, Bagnoli F, et al. Protectome analysis: a new selective bioinformatics tool for bacterial vaccine candidate discovery[J]. Mol Cell Proteomics, 2015, 14(2): 418-429.
|